

Comprehensive Lab Interpretation - 2025-11-12

Patient: Chad T. Mansfield

Interpreted by: Case study automation (reviewed manually)

Context: Post-fast labs under sustained hepatic insulin resistance, low ketone generation, and suspected HPA/mitochondrial dysregulation.

- 1. Metabolic / Endocrine Findings

- **Fasting glucose 131 mg/dL + insulin 10.5 µIU/mL** → confirms hepatic insulin resistance rather than pancreatic failure.
- **Absent β-hydroxybutyrate (<0.2 mmol/L)** after prolonged fast → impaired mitochondrial β-oxidation.
- **C-peptide normal** → endogenous insulin still produced; not an autoimmune form.
- **Cortisol 11 µg/dL (AM) with DHEA-S 42 µg/dL** → catabolic-dominant adrenal profile.
- **ACTH normal** → central drive intact.
- Pattern = *stress-adaptive glucose maintenance with suppressed androgenic output*.

Mechanistic link:

Persistent cortisol tone blunts hepatic ketogenesis and inhibits CPT-1 via malonyl-CoA accumulation. Low DHEA-S implies reduced 17,20-lyase flux (CYP17A1), likely secondary to mitochondrial NADPH imbalance.

- 2. Hepatic / Renal

- **ALT 46 U/L** → mild hepatic strain, possibly from oxidative load (TRT, mitochondrial inefficiency).
- **AST normal** → no necrotic injury.
- **Bilirubin, albumin, eGFR normal** → intact hepatic synthesis and renal clearance.

Interpretation:

Supports *metabolic rather than structural* liver stress; reversible with improved redox control and insulin sensitivity.

- 3. Lipid Panel

- LDL-C 106, HDL 48, TG 112 → moderate-normal lipids with insulin-resistant pattern (LDL slightly high, TG near normal).
 - When combined with fasting glucose pattern → suggests selective hepatic insulin resistance (VLDL production active, peripheral insulin sensitivity preserved).
-

- 4. Hematologic

- Platelets 143 K/ μ L → borderline low; may reflect catecholamine stress or marrow suppression secondary to cortisol.
 - Hemoglobin and indices normal.
 - Consistent with transient redistribution rather than pathology.
-

- 5. Inflammatory / Nutritional

- hs-CRP 1.1 mg/L → minimal systemic inflammation.
 - Ferritin 82 ng/mL → adequate stores, no anemia of chronic disease.
 - B12/Folate normal → methylation support adequate.
-

- 6. Thyroid

- TSH 2.4 with normal FT3/FT4 → euthyroid.
 - Reverse T3 19 → mild adaptive upregulation, expected under fasting stress.
 - No evidence of primary hypothyroidism.
-

- 7. Integrated Mechanistic Summary

- Pattern = **HPA-driven, hepatic-selective insulin resistance with suppressed mitochondrial ketogenesis.**
 - **Cortisol > DHEA-S** ratio remains high → consistent with chronic sympathetic activation.
 - **TRT + aromatase control** improving androgen stability but does not fully restore DHEA or mitochondrial coupling.
 - **Metformin** previously ineffective due to redox burden; **tirzepatide** directly targets glucagon suppression and hepatic insulin signaling.
-

- 8. Clinical Correlation & Next Steps

- Reinforces tirzepatide renewal rationale (GLP-1/GIP support of hepatic insulin signaling).
 - Suggests monitoring **AST/ALT, DHEA-S, and β-hydroxybutyrate** with each therapy change.
 - Recommend exploring **mitochondrial redox cofactors** (R-lipoate, carnitine, NAD+ precursors).
 - Consider early-morning cortisol-DHEA ratio trend to gauge HPA recalibration.
-

Conclusion:

Findings are consistent with metabolic inflexibility secondary to mitochondrial dysfunction and HPA overactivity, improving under incretin therapy.

Data integration will be added to `data/labs_trend.csv` for longitudinal modeling.